Stryker (SYK)
(Delayed Data from NYSE)
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$369.02 USD
-0.84 (-0.23%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $369.15 +0.13 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum D VGM
Zacks News
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
by Zacks Equity Research
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
by Zacks Equity Research
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
by Zacks Equity Research
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth
by Zacks Equity Research
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
by Zacks Equity Research
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
by Zacks Equity Research
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
by Zacks Equity Research
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
The Zacks Analyst Blog Highlights Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines
by Zacks Equity Research
Disney, Morgan Stanley, Stryker, Shopify and Delta Air Lines are included in this Analyst Blog.
Top Stock Reports for Disney, Morgan Stanley & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Morgan Stanley (MS) and Stryker Corporation (SYK).
Reasons to Add Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
Walgreens' (WBA) AllianceRx Pharmacy Will Distribute VIVJOA
by Zacks Equity Research
Walgreens' (WBA) specialty pharmacy patients now have exclusive access to 240+ limited distribution drugs.
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
by Zacks Equity Research
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
Align Technology (ALGN) Gains From Innovation, Macro Issues Ail
by Zacks Equity Research
In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
by Zacks Equity Research
The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
Here's Why You Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.